Breaking Finance News

A report released earlier today by Vetr Inc. about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ups the target price to $88.25

Just yesterday Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded -4.64% lower at $80.38. Vertex Pharmaceuticals Incorporated’s 50-day moving average is $83.91 and its 200-day moving average is $89.91. The last closing price is down -13.45% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 0 shares of VRTX traded hands, down from an avg. volume of 1,805,600

Reporting a potential upside of 0.10%, Vetr Inc. upped the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $88.25

Performance Chart

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

With a total market value of $0, Vertex Pharmaceuticals Incorporated has with a one year low of $73.31 and a one year high of $133.41 .

A total of 20 analysts have released a research note on Vertex Pharmaceuticals Incorporated. Eight analysts rating the company a strong buy, ten analysts rating the company a buy, seven analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $110.30.

More About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.